Characterizing the Course of Suicidal Ideation Response to Ketamine

No pharmacological treatments exist for active suicidal ideation (SI), but the glutamatergic modulator ketamine elicits rapid changes in SI. We developed data-driven subgroups of SI trajectories after ketamine administration, then evaluated clinical, demographic, and neurobiological factors that might predict SI response to ketamine.

View Abstract

Related Authors

Erica Martin Richards, M.D., Ph.D.

Erica Martin Richards, MD, PhD

Chair and Medical Director, Department of Psychiatry and Behavioral Health, Sibley Memorial Hospital

View full profile


Connect with Sibley Hospital

Connect with Surburban Hospital

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Powered by the BroadcastMed Network